A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

March 2, 2021

Study Completion Date

March 2, 2021

Conditions

Healthy

Interventions

DRUG

14C-lazertinib

A single oral dose of 14C-lazertinib will be administered.

Trial Locations (1)

PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT04410081 - A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants | Biotech Hunter | Biotech Hunter